AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01495728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation - Thoracic Spine
Description: Mid and Upper Thoracic Spine
Study NCT01495728 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: Mid and Upper Thoracic Spine
Study NCT03114748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS switched OFF and ON
Study NCT02352142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Full Term EEG
Description: Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
Study NCT02352142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Infant Care
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study NCT01302171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony stimulating factor (GCSF)
Description: 10mcg/kg per day 5 days
Study NCT01302171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cells
Description: intra coronary injection of stem cells or placebo
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Study NCT00847613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Study NCT03022461 — intervention group
Intervention type: OTHER
Intervention: Long term follow-up
Study NCT04468672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portion size
Description: The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
Study NCT03080987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 0.3 mg/kg
Description: JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
Study NCT03080987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 1.0 mg/kg
Description: JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
Study NCT03080987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 2.5 mg/kg
Description: JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
Study NCT03080987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
Study NCT03080987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 (Dose to be Determined)
Description: JNJ-64179375 IV infusion (Dose to be determined).
Study NCT03308630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga based Energy Alignment and Mantra
Description: Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated.
Study NCT01609283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells
Study NCT00845429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine - cell based (2007-2008 Formulation)
Description: 0.5 mL, Intramuscular
Study NCT00845429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine - cell-based (2007-2008 Formulation)
Description: 1.0 mL, Intramuscular
Study NCT00845429 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus vaccine (2007-2008 Formulation)
Description: 0.5 mL, Intramuscular
Study NCT02631304 — intervention group
Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
Study NCT02716376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otovent®
Description: Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
Study NCT04155879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
Study NCT04155879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Electrical or pharmacologic restoration of sinus rhythm
Study NCT02039557 — intervention group
Intervention type: GENETIC
Intervention: NiCord®/CordIn™ (omidubicel)
Study NCT02975128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLES system and conventional lumpectomy
Description: Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
Study NCT03220802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNI-BiOTiC PPI
Description: The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
Study NCT00448591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
Study NCT00448591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Description: As prescribed
Study NCT03832530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer conception counseling inclusive of periconception PrEP
Description: Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
Study NCT02392195 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Observational
Study NCT02598323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study NCT00933530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRT2104
Description: SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
Study NCT00933530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
Study NCT02028715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Study NCT02028715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Study NCT03264352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
Study NCT03264352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study NCT03264352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment by current guideline
Description: No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
Study NCT01783366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TUBE EXCHANGER
Study NCT04048096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill Oil
Description: Aker Biomarine Superba Krill Oil
Study NCT04048096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mixed vegetable oil
Study NCT02563561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: One dose of apaziquone administered by intravesical administration
Study NCT02563561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
Study NCT02458495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes MAP Intervention
Study NCT02563561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
Study NCT05801315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing
Description: Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
Study NCT05801315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth ultrasonic debridement
Description: Peri-implant mucositis sites are treated with thin ultrasonic tips.
Study NCT05801315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full mouth ultrasonic debridement
Description: Peri-implant mucositis sites are treated with thin ultrasonic tips.
Study NCT00937898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOLD+ Diet
Description: Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
Study NCT00937898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD+ Diet
Description: Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
Study NCT00937898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOLD diet
Description: Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
Study NCT00937898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD diet
Description: Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
Study NCT02054117 — intervention group
Intervention type: OTHER
Intervention: Intracerebral Hemorrhage
Description: Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Study NCT04273789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far infrared reflecting sleepwear
Description: 100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
Study NCT04273789 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sleepwear
Description: 100% microlyocell sleepwear (shorts + shirt)
Study NCT02541903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilotrif
Description: Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
Study NCT03822416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
Study NCT03822416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT01610245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT01660789 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity, dietary counseling, coaching
Description: Physical activity, dietary counseling, coaching
Study NCT03822416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
Study NCT03822416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information
Description: Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
Study NCT03822416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
Study NCT00817219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate ointment
Description: Once daily application for 4 weeks
Study NCT00723047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrin glue injection in fistula
Study NCT02258347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Study NCT02827266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Study NCT04640402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Study NCT04197492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
Study NCT04197492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
Study NCT01990391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brazil nut flour
Description: The Brazil nut group received 13g/day of Brazil nut flour during three months.
Study NCT01990391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (cassava flavored flour)
Description: The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months